M&A Deal Summary

Clario Acquires Biomedical Systems

On September 8, 2017, Clario acquired life science company Biomedical Systems

Acquisition Highlights
  • This is Clario’s 2nd transaction in the Life Science sector.
  • This is Clario’s 5th transaction in the United States.
  • This is Clario’s 1st transaction in Missouri.

M&A Deal Summary
Date 2017-09-08
Target Biomedical Systems
Sector Life Science
Buyer(s) Clario
Deal Type Add-on Acquisition

Target

Biomedical Systems

St. Louis, Missouri, United States
website
Biomedical Systems Corp. is a provider of reliable imaging as well as cardiac safety and respiratory data collection solutions. Biomedical Systems Corp. was founded in 1975 and is headquartered in St. Louis, Missouri.

Search 193,240 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Clario

Philadelphia, Pennsylvania, United States

website

Category Company
Founded 1972
Sector Medical Products
Employees3,800
DESCRIPTION

Clario offers a compelling combination of technology, services, and clinical expertise, helping customers to deliver successful clinical trial outcomes by ensuring high-quality data capture, reduced costs, and shortened study timelines. Clario was founded in 1972 and is based in Philadelphia, Pennsylvania.

DEAL STATS #
Overall 6 of 10
Sector (Life Science) 2 of 3
Type (Add-on Acquisition) 4 of 7
State (Missouri) 1 of 1
Country (United States) 5 of 8
Year (2017) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-12-08 Exco InTouch

Sawbridgeworth, United Kingdom

Exco InTouch Ltd. is a provider of mobile patient communication and management solutions for the pharmaceutical and healthcare sector.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-12-04 iCardiac Technologies

Rochester, New York, United States

iCardiac Technologies, Inc. is a provider of advanced cardiac safety analysis technologies. The company evolved from research carried out at the Heart Research Follow-up Program at the University of Rochester. The company's technology provides more rigorous characterization of the cardiac safety profiles of in-development and on-market drugs.

Buy -
Mergr

Product

Company

Legal